3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
pazopanib
5
Doxorubicin
3
Bevacizumab
3
carotuximab
2
Sorafenib
2
Radiotherapy, Conformal
2
Paclitaxel
2
Gemcitabine
2
tremelimumab
1
trebananib
1
temsirolimus
1
talimogene laherparepvec
1
romidepsin
1
regorafenib
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
cixutumumab
1
Watchful Waiting
1
Vascular Endothelial Growth Factor A
1
TTI-621
1
Sunitinib
1
Sirolimus
1
Razoxane
1
Observation
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
HhAntag691
1
Fluorodeoxyglucose F18
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Hemangiosarcoma
×
pertuzumab
×
Clear all
No trials found.